Atorvastatin and rosuvastatin: align the comparison first.

Start with the dossier for the product in hand

Before comparing, open the dossier that corresponds to the product in hand. Check its market scope, electronic label, source documents and reviewed pharmacovigilance records; a shared or similar medicine name does not replace this check.

Open the Lipitor / atorvastatin dossier　·　Open the Crestor / rosuvastatin dossier

Four checks before calling it a comparison

1. Check a specific pack, not just a medicine name. Bring the brand, generic name, stated strength per unit, dosage form, target market and label version. A shared “statin” class or a similar name does not establish interchangeability.
2. mg identifies a product; it does not answer “how many tablets today?” Official labels list different tablet strengths and product- or co-medication-specific boundaries. This page does not turn pack strength into a personal tablet count.
3. Do not read “same class” as permission to combine, alternate or replace products yourself. Both are statins. A clinician or pharmacist needs the complete medicine list, prior reactions and current label to assess any switch, combination, stop or adjustment.
4. List prescription medicines, OTC products, supplements and herbs together. Both official labels identify co-medications that can change risk or need adjustment. One webpage cannot deliver an individual “safe” or “unsafe” conclusion.

Genetic results and concerning symptoms: this page helps prepare questions

The current U.S. CRESTOR label includes a pharmacogenomics section. That does not mean everyone should be screened, and an existing report does not replace product verification, medical history or professional judgement. If an original testing report already exists, bring it with the medicine list and pack for a clinician or pharmacist to assess relevance.

Both labels instruct patients to promptly report unexplained muscle pain, tenderness or weakness, especially with malaise or fever, to a healthcare professional. This page does not diagnose the cause or tell an individual to stop, add or switch a medicine.

Four questions for the prescriber or pharmacist

1. Does the specific product, dosage form and strength I have match the current prescription?
2. Which medicines, supplements, herbs and dietary habits need to be reviewed together?
3. If muscle symptoms or another suspected adverse effect occurs, who should assess it promptly and how?
4. Which existing test results or health records are relevant to this product check?

Price publication gate

Only complete records for the same market and the same product definition enter a comparison. If any field is missing, the platform does not calculate a unit cost or make a cross-market price conclusion.

1. Target market and capture date
2. Brand/generic name, approval record and originator or generic verification status
3. Dosage form, route, strength and pack size
4. Channel, prescription path and availability status
5. Amount, currency, tax and reimbursement or discount basis
6. Accessible source, collector and review version

How a U.S. per-unit benchmark is admitted

CMS NADAC can enter editorial review as a U.S. retail-community-pharmacy acquisition-cost benchmark per unit, on the official update cadence. It is not a retail price, patient out-of-pocket amount or reimbursement decision. Each row still needs an NDC-to-product identity match, current target-market label, dosage form, strength, pack and human review before it could be shown as public price material. Its rate-setting classification does not establish originator or generic identity.

Official price and reimbursement entry points

These entry points identify reviewable market-specific price or reimbursement bases. Until the product, presentation, date and source are reviewed together, the platform does not derive a price conclusion from them.

• United States · CMS / Medicaid 2026 NADAC dataset ↗reviewed 2026-08-20

  Weekly pharmacy acquisition-cost reference; not a retail, patient out-of-pocket or cross-channel price.

• United Kingdom (NHS England/Wales pathway) · NHSBSA Drug Tariff ↗reviewed 2026-08-20

  NHS contractor reimbursement, fees and rules; not a private-prescription or retail price.

• Australia · Australian PBS Medicine Search ↗Official lookup entry · reviewed 2026-08-20

  Government-subsidised schedule and its pricing basis; actual patient payment still depends on eligibility, premiums and pharmacy conditions.

• Japan · MHLW NHI drug-price notices ↗Official lookup entry · reviewed 2026-08-20

  National insurance claim-price notices; they do not automatically equal an individual's payment.